Market Research Company

Human Insulin Market Share, Size, Trends, Forecast and Analysis of Key players 2025

Press release   •   Mar 09, 2020 09:36 EDT

​According to the latest report by IMARC Group, the global human insulin market to reach a value of US$ 58.3 Billion by 2025, exhibiting a CAGR of around 9% during 2020-2025.

Insulin is a hormone produced by the pancreas that helps in blood sugar metabolism in the body. Human insulin refers to a synthetic version of the hormone, which is produced by growing the insulin proteins within E-coli bacteria (Escherichia coli). It is prescribed to people who have diabetes to regulate fat and carbohydrate metabolism in the body. It is either taken orally or through devices, such as syringes, injection pens and pumps.

The rising prevalence of diabetes and obesity around the world represents one of the key factors driving the global human insulin market growth. In addition to this, the growing geriatric population, sedentary lifestyles and unhealthy dietary patterns are leading to an increase in incidences of metabolic disorders, which in turn, is catalyzing the demand for human insulin across the globe. Moreover, technological advancements in insulin delivery devices, such as implantable pumps, inhalers and jet injectors, are expected to propel the market growth in the coming years.

Request for a sample copy of this report: https://www.imarcgroup.com/human-insulin-market/requestsample

Insights on Market Segmentation:

  • Breakup by Product:
  • Drugs
  • Delivery Devices

Breakup by Distribution Channel:

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Retail Stores
  • Others

Breakup by Disease Type:

  • Type I Diabetes
  • Type II Diabetes

Breakup by Region:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • Middle East and Africa

View Report TOC, Figures and Tables: https://www.imarcgroup.com/human-insulin-market

Competitive Landscape:

The competitive landscape of the industry has also been examined with some of the key players being: B. Braun Melsungen AG, Becton Dickinson and Co NYSE: BDX 239.12 USD +0.79 (0.33%), BIOCON LTD. (BIOCON.BO), Eli Lilly and Company (LLY), Julphar, Novo Nordisk A/S (NVO), Pfizer, Sanofi, Sedico, Wockhardt, Ypsomed Holding, etc.

Contact Us

30 N Gould St
Ste R
Sheridan, WY 82801
USA
Email: sales@imarcgroup.com
Website: https://www.imarcgroup.com
Follow us on twitter: @imarcglobal

IMARC is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products and services cover major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

With close cooperation at all levels of the client organization, IMARC’s tailored approach ensures that our clients achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting results. IMARC serves clients on a wide array of issues, regardless of industry sector. Our offerings fall under following areas:

1. Market Research
2. Business Strategy
3. Consulting and Advisory Services
4. Procurement and Supply Chain Management
5. Business Intelligence